MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$83,340K
EPS
-$3.1
Unit: Thousand (K) dollars
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
General and administrative
-
-
-
5,154*
Total revenues
0
0
-
369
Acquired in-process research and development
45,000
0
-
-42,001*
Research and development
35,529
24,817
24,600
43,250*
General and administrative
8,099
6,502
6,179
-
Reversal due to settlement of indirect tax liabilities
0
-3,935
-5,510
-
Total operating expenses
88,628
27,384
25,269
6,403
Loss from operations
-88,628
-27,384
-25,269
-6,034*
Other expense, net
0
0
110
-
Interest income, net
5,395
1,666
1,899
362
Total other income, net
5,395
1,666
1,789
362*
Net loss from continuing operations before income tax expense
-
-
-
-5,673
Net loss from continuing operations
-83,233
-25,718
-23,480
-5,673*
(gain) income from discontinued operations (including gain on disposal of discontinued operations of zero and 1,799 during the three and nine months ended september 30, 2024, respectively), net of income taxes
0
0
-
-3,362*
Net loss
-83,233
-25,718
-23,480
-9,036
Unrealized loss on available-for-sale investments
-107
-
-
-
Comprehensive loss
-83,340
-
-
-
Basic EPS
-3.1
-1.65
-1.66
-1.136
Diluted EPS
-3.1
-1.65
-1.66
-1.136
Basic Average Shares
26,882,366
15,547,403
14,177,743
7,955,010
Diluted Average Shares
26,882,366
15,547,403
14,177,743
7,955,010
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Comprehensive loss-$83,340K Net loss-$83,233K (-420.69%↓ Y/Y)Unrealized loss onavailable-for-sale investments-$107K Interest income, net$5,395K (190.21%↑ Y/Y)Net loss fromcontinuing operations-$83,233K (-435.78%↓ Y/Y)Total other income,net$5,395K (190.21%↑ Y/Y)Loss from operations-$88,628K (-409.53%↓ Y/Y)Total operatingexpenses$88,628K (409.53%↑ Y/Y)Acquired in-processresearch and development$45,000K Research and development$35,529K (185.86%↑ Y/Y)General andadministrative$8,099K (63.12%↑ Y/Y)

Cidara Therapeutics, Inc. (CDTX)

Cidara Therapeutics, Inc. (CDTX)